- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07723508
BeauSaki Bird's Nest Peptide Efficacy
Efficacy Evaluation of BeauSaki Edible Bird's Best Peptide Product
The goal of this clinical trial is to learn whether BeauSaki Edible Bird's Nest Peptide Product can improve facial skin conditions in healthy adult participants. The main questions it aims to answer are:
Can daily intake of the edible bird's nest peptide product improve facial skin hydration, elasticity, brightness, wrinkles, pores, spots, redness, and skin texture after 8 weeks?
Is the edible bird's nest peptide product well tolerated by participants during the study period?
Researchers will compare participants who take the edible bird's nest peptide capsule with participants who take a placebo capsule without edible bird's nest to see if the product improves facial skin conditions.
Participants will:
- Take one capsule daily for 8 weeks.
- Visit the study site at baseline, week 4, and week 8 for non-invasive facial skin assessments.
- Cleanse their face with water and rest under room temperature conditions for 30 minutes before each skin assessment.
- Complete a brief questionnaire about perceived skin condition and product satisfaction at baseline, week 4, and week 8.
- Have facial photographs taken for skin condition evaluation, with identifiable areas masked before disclosure.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Taiwan
-
Tainan, Taiwan, Taiwan, 71710
- Chia Nan University of Pharmacy & Science
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Participants aged over 18 years.
Exclusion Criteria:
- Individuals who are unwilling to participate voluntarily.
- Individuals diagnosed by a physician with skin disease, liver cirrhosis, or chronic renal failure.
- Individuals with known allergies to cosmetics, drugs, or foods.
- Pregnant or breastfeeding individuals.
- Individuals taking medications for chronic diseases.
- Students taught by the principal investigator.
- Individuals unwilling to allow their study-related photographs to be disclosed. Vegetarians.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: BeauSaki Edible Bird's Nest Peptide Group
Participants in this group will take one capsule of BeauSaki Edible Bird's Nest Peptide Product daily for 8 weeks.
|
Participants will take one capsule daily for 8 weeks.
|
|
Placebo-jämförare: Placebo Group
Participants in this group will take one placebo capsule without edible bird's nest daily for 8 weeks.
|
Participants will take one placebo capsule without edible bird's nest daily for 8 weeks.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Facial Skin Analysis Parameters
Tidsram: Baseline, week 4, and week 8
|
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin spots, wrinkles, texture, pores, UV spots, brown Spots, red areas, porphyrins. Units: arbitrary units. Facial skin condition will be assessed using non-invasive image-based facial skin analysis. Changes from baseline will be evaluated at week 4 and week 8. |
Baseline, week 4, and week 8
|
|
Skin Moisture
Tidsram: Baseline, week 4, and week 8
|
Skin moisture meter (VapoMeter) was utilized to measure skin moisture.
Units: g/m²h Facial skin condition will be assessed using non-invasive image-based facial skin analysis.
Changes from baseline will be evaluated at week 4 and week 8.
|
Baseline, week 4, and week 8
|
|
Skin elasticity
Tidsram: Baseline, week 4, and week 8
|
Skin elastometer (Soft Plus) was utilized to measure skin elasticity.
Units: arbitrary units.
Facial skin condition will be assessed using non-invasive image-based facial skin analysis.
Changes from baseline will be evaluated at week 4 and week 8.
|
Baseline, week 4, and week 8
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- TMSHIRB25-104-B
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .